Cargando…

Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam

Background: Risk communication is necessary to improve the booster vaccination rate, but Vietnam does not have a system to collect and disclose such information. Therefore, the purpose of this study was to clarify adverse reactions and their frequency in the early period after booster vaccination, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Duy Cuong, Dao, Thi Loi, Truong, Thi Minh Dieu, Nguyen, Thu Huong, Phan, Thu Nga, Nguyen, Ha My, Pham, Thi Dung, Nguyen, Xuan Bai, Nguyen, Thanh Binh, Hoang, Van Thuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414515/
https://www.ncbi.nlm.nih.gov/pubmed/36016213
http://dx.doi.org/10.3390/vaccines10081325
_version_ 1784776006795526144
author Nguyen, Duy Cuong
Dao, Thi Loi
Truong, Thi Minh Dieu
Nguyen, Thu Huong
Phan, Thu Nga
Nguyen, Ha My
Pham, Thi Dung
Nguyen, Xuan Bai
Nguyen, Thanh Binh
Hoang, Van Thuan
author_facet Nguyen, Duy Cuong
Dao, Thi Loi
Truong, Thi Minh Dieu
Nguyen, Thu Huong
Phan, Thu Nga
Nguyen, Ha My
Pham, Thi Dung
Nguyen, Xuan Bai
Nguyen, Thanh Binh
Hoang, Van Thuan
author_sort Nguyen, Duy Cuong
collection PubMed
description Background: Risk communication is necessary to improve the booster vaccination rate, but Vietnam does not have a system to collect and disclose such information. Therefore, the purpose of this study was to clarify adverse reactions and their frequency in the early period after booster vaccination, and to obtain primary data for improving the booster vaccination rate. Methods: A cross-sectional survey was conducted among adults aged ≥18 years. Clinical data were collected 14 days after booster vaccination by using a standard questionnaire. Results: A total of 1322 participants were included with median age = 23 and sex ratio (Male/Female) = 0.53. AstraZeneca was the most commonly used vaccine for the first and second doses, while Pfizer was the most commonly used vaccine for booster shots. Injection site pain, fatigue, and myalgia were the most common side effect reported (71.9%, 28.1%, and 21.8%, respectively). Compared to previous COVID-19 vaccine injections, 81.9% of participants reported that their symptoms were similar or milder after receiving the booster dose. They were more likely to present injection site pain (OR = 1.43, p < 0.0001) and lymphadenopathy (OR = 4.76, p < 0.0001) after receiving the booster shot. Fever (OR = 0.33, p < 0.0001) and fatigue (OR = 0.77, p = 0.002) were less often reported after booster shots compared to the first and second injections. The severity of symptoms occurring after booster dose versus first and second doses increased significantly with each additional year of age and among participants receiving the Pfizer and Moderna vaccines. Conclusion: Adverse reactions to booster vaccination are minor and their incidence is the same as for the first or the second vaccination. Multicenter studies with larger sample sizes on the side effects and safety of COVID-19 vaccine booster shots need to be conducted to make the population less worried, in order to increase the vaccination rate, to protect individuals’ and communities’ health.
format Online
Article
Text
id pubmed-9414515
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94145152022-08-27 Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam Nguyen, Duy Cuong Dao, Thi Loi Truong, Thi Minh Dieu Nguyen, Thu Huong Phan, Thu Nga Nguyen, Ha My Pham, Thi Dung Nguyen, Xuan Bai Nguyen, Thanh Binh Hoang, Van Thuan Vaccines (Basel) Article Background: Risk communication is necessary to improve the booster vaccination rate, but Vietnam does not have a system to collect and disclose such information. Therefore, the purpose of this study was to clarify adverse reactions and their frequency in the early period after booster vaccination, and to obtain primary data for improving the booster vaccination rate. Methods: A cross-sectional survey was conducted among adults aged ≥18 years. Clinical data were collected 14 days after booster vaccination by using a standard questionnaire. Results: A total of 1322 participants were included with median age = 23 and sex ratio (Male/Female) = 0.53. AstraZeneca was the most commonly used vaccine for the first and second doses, while Pfizer was the most commonly used vaccine for booster shots. Injection site pain, fatigue, and myalgia were the most common side effect reported (71.9%, 28.1%, and 21.8%, respectively). Compared to previous COVID-19 vaccine injections, 81.9% of participants reported that their symptoms were similar or milder after receiving the booster dose. They were more likely to present injection site pain (OR = 1.43, p < 0.0001) and lymphadenopathy (OR = 4.76, p < 0.0001) after receiving the booster shot. Fever (OR = 0.33, p < 0.0001) and fatigue (OR = 0.77, p = 0.002) were less often reported after booster shots compared to the first and second injections. The severity of symptoms occurring after booster dose versus first and second doses increased significantly with each additional year of age and among participants receiving the Pfizer and Moderna vaccines. Conclusion: Adverse reactions to booster vaccination are minor and their incidence is the same as for the first or the second vaccination. Multicenter studies with larger sample sizes on the side effects and safety of COVID-19 vaccine booster shots need to be conducted to make the population less worried, in order to increase the vaccination rate, to protect individuals’ and communities’ health. MDPI 2022-08-16 /pmc/articles/PMC9414515/ /pubmed/36016213 http://dx.doi.org/10.3390/vaccines10081325 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nguyen, Duy Cuong
Dao, Thi Loi
Truong, Thi Minh Dieu
Nguyen, Thu Huong
Phan, Thu Nga
Nguyen, Ha My
Pham, Thi Dung
Nguyen, Xuan Bai
Nguyen, Thanh Binh
Hoang, Van Thuan
Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam
title Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam
title_full Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam
title_fullStr Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam
title_full_unstemmed Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam
title_short Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam
title_sort short-term adverse effects immediately after the start of covid-19 booster vaccination in vietnam
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414515/
https://www.ncbi.nlm.nih.gov/pubmed/36016213
http://dx.doi.org/10.3390/vaccines10081325
work_keys_str_mv AT nguyenduycuong shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT daothiloi shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT truongthiminhdieu shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT nguyenthuhuong shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT phanthunga shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT nguyenhamy shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT phamthidung shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT nguyenxuanbai shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT nguyenthanhbinh shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam
AT hoangvanthuan shorttermadverseeffectsimmediatelyafterthestartofcovid19boostervaccinationinvietnam